Many people are surprised to learn that ovarian cancer is not one disease, but several distinct types and subtypes. Each type differs in who it typically affects, how it spreads, how it’s treated, and its prognosis. High grade serous ovarian cancer (HGSOC) is the most common, and is often the unspoken type we refer to … Continued
Before we head into the long holiday weekend, we wanted to share all the latest news and happenings. See below for updates in ovarian cancer research and advocacy, and discover new ways to get support and get involved. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
New research from The Wistar Institute and Peter MacCallum Cancer Center has uncovered a previously unknown checkpoint mechanism for gene expression, that may open up new avenues for transcription-based targeted cancer therapies in the future. This exciting study, published in the cancer journal Cell, was made possible in part by an OCRA research grant to … Continued
Flowers are blooming all around us, people are beginning to rediscover the things that matter most, and every day, OCRA grantees are making strides in understanding even more about ovarian cancer. Happy (almost!) May! RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
On April 9, President Biden released his discretionary funding request for fiscal year 2022. Within the request, the President announced the creation of an agency that would take on high-risk, high-reward health research seeking to advance medical technologies. The agency is modeled after the renowned Defense Advanced Research Projects Agency (DARPA) which leverages public investments … Continued
On Friday, March 19, U.S. House Representatives Grace Meng (D-NY), Brian Fitzpatrick (R-PA), and Norma Torres (D-CA) released a bipartisan “Dear Colleague” letter urging the House Appropriations Defense Subcommittee to fund the Ovarian Cancer Research Program (OCRP) at $45 million for Fiscal Year 2022, an increase of $10 million over last year. OCRP is the only federally-funded … Continued
The snow is (finally!) melting in the areas where many of us at OCRA work and live, the COVID vaccine is rolling out, and there is so much work being done to improve the lives of the ovarian cancer community … we can’t help but feel hopeful. Read on to discover the latest, and perhaps … Continued
OCRA’s Spring Advocacy Day, held March 8-9, looked a little bit different this year. For starters, we met online rather than in Washington D.C. But while the natural and obvious reaction to virtual life is to focus on what we’ve lost, we’re choosing to focus on all that we’ve gained from having to move our … Continued
Each year, OCRA honors individuals doing important and notable work in the ovarian cancer field with a research prize to help propel their future discoveries. Individuals are selected by members of OCRA’s Scientific Advisory Committee. Dr. Sarah Adams Awarded Liz Tilberis Research Prize for Outstanding Early Career Investigators The Liz Tilberis Research Prize is awarded … Continued
As we gear up for our first ever virtual Spring Advocacy Day — which will welcome more than 200 participants, double our usual crowd! — we couldn’t help but take a moment and look back. In a year when the world all but shut down, we accomplished quite a lot on a policy level, thanks … Continued
Imagine, if you will, a scene from yesteryear: rows of telephone operators sitting in front of giant switchboards, lights blinking on and off in seemingly random patterns, hands working quickly to plug and unplug wires in order to foster connections. If you can picture that, you can begin to get a sense of the impact … Continued
PARP inhibitors have proven to be particularly valuable in improving progression-free survival for patients with certain types of ovarian cancer. But unfortunately, these gains come at a high financial cost to many patients, with a recent study showing that Medicare beneficiaries are the hardest hit. A team of researchers from The University of Alabama at … Continued
Get email updates about research news, action alerts, and ways to join the fight.
